Ribociclib (LEE011)

For research use only. Not for use in humans.

目录号：S7440 中文名称：瑞博西利，瑞博西林

CAS No. 1211441-98-3

Ribociclib (LEE011) 是一种具有口服活性的、高度特异性的CDK4和CDK6抑制剂，对应的IC50值分别为10 nM和39 nM。Phase 3。

规格

价格

库存

购买数量

10mM (1mL in DMSO)	RMB 2432.43	现货
5mg	RMB 1614.88	现货
25mg	RMB 4832.1	现货
大包装	有超大折扣

大剂量询单有大折扣!

今日订购，明日送达，全国免运费！

全国免费电话：400-668-6834 | Email：info@selleck.cn

客户使用Selleck生产的Ribociclib (LEE011)发表文献59篇：

Cancer Cell, 2021, S1535-6108(21)00492-X

PubMed: 34624218 ( click the link to review the publication )

Nat Med, 2019, 25(2):292-300

PubMed: 30664779 ( click the link to review the publication )

Nat Genet, 2019, 51(3):506-516

PubMed: 30718927 ( click the link to review the publication )

Cancer Discov, 2019, 10.1158/2159-8290.CD-18-0830

PubMed: 31594766 ( click the link to review the publication )

Nature, 2018, 553(7686):91-95

PubMed: 29160310 ( click the link to review the publication )

Cancer Cell, 2018, 34(6):893-905

PubMed: 30537512 ( click the link to review the publication )

Nat Commun, 2021, 12(1):3356

PubMed: 34099663 ( click the link to review the publication )

Cancers (Basel), 2021, 13(3)E372

PubMed: 33498427 ( click the link to review the publication )

Cancer Discov, 2021, candisc.1540.2020

PubMed: 33941591 ( click the link to review the publication )

Biochim Biophys Acta Mol Cell Res, 2021, 1868(7):119044

PubMed: 33865884 ( click the link to review the publication )

Liver Int, 2021, 41(3):608-620

PubMed: 33179425 ( click the link to review the publication )

Mol Cancer Res, 2021, 19(6):1026-1039

PubMed: 33627502 ( click the link to review the publication )

Front Oncol, 2021, 11:681530

PubMed: 34277427 ( click the link to review the publication )

Int J Mol Sci, 2021, 22(6)2915

PubMed: 33805656 ( click the link to review the publication )

Breast Cancer, 2021, 10.1007/s12282-021-01282-5

PubMed: 34346034 ( click the link to review the publication )

Nat Commun, 2020, 11(1):5305

PubMed: 33082317 ( click the link to review the publication )

Genome Med, 2020, 18;12(1):17

PubMed: 32070411 ( click the link to review the publication )

Elife, 2020, 7;9:e44571

PubMed: 32255427 ( click the link to review the publication )

Eur J Cancer, 2020, 126:93-103

PubMed: 31927215 ( click the link to review the publication )

Cancers (Basel), 2020, 12(3)

PubMed: 32197329 ( click the link to review the publication )

Int J Mol Sci, 2020, 18;21(8):2825

PubMed: 32325639 ( click the link to review the publication )

Cancer Cell Int, 2020, 20:253

PubMed: 32565737 ( click the link to review the publication )

Open Biol, 2020, 10(10):200200

PubMed: 33052073 ( click the link to review the publication )

Breast Cancer, 2020, 10.1007/s12282-020-01090-3

PubMed: 32297248 ( click the link to review the publication )
Mol Cell, 2019, 76(4):562-573

PubMed: 31543423 ( click the link to review the publication )

Hepatology, 2019, 10.1002/hep.30704

PubMed: 31077409 ( click the link to review the publication )

Nat Commun, 2019, 10(1):558

PubMed: 30718512 ( click the link to review the publication )

Cell Rep, 2019, 26(10):2667-2680

PubMed: 30840889 ( click the link to review the publication )

Oncogene, 2019, 38(20):3886-3902

PubMed: 30692638 ( click the link to review the publication )

Mol Cancer Ther, 2019, 10.1158/1535-7163.MCT-19-0162

PubMed: 31395685 ( click the link to review the publication )

Cancer Biol Med, 2019, 16(2):264-275

PubMed: 31516747 ( click the link to review the publication )

Cancer Biol Med, 2019, 16(1):66-83

PubMed: 31119047 ( click the link to review the publication )

NPJ Precis Oncol, 2019, 03:18

PubMed: 31341951 ( click the link to review the publication )

Oncotarget, 2019, 10(47):4907-4918

PubMed: 31448056 ( click the link to review the publication )

Nat Chem Biol, 2018, 14(8):768-777

PubMed: 29942081 ( click the link to review the publication )

Clin Cancer Res, 2018, 24(16):3994-4005

PubMed: 29716919 ( click the link to review the publication )

Cell Death Dis, 2018, 9(10):944

PubMed: 30237504 ( click the link to review the publication )

Cell Death Dis, 2018, 9(9):918

PubMed: 30206211 ( click the link to review the publication )

Eur J Med Chem, 2018, 144:1-28

PubMed: 29247857 ( click the link to review the publication )

Biochem Pharmacol, 2018, 153:230-241

PubMed: 29408328 ( click the link to review the publication )

Mol Carcinog, 2018, 57(4):469-482

PubMed: 29240261 ( click the link to review the publication )

Exp Ther Med, 2018, 15(2):1831-1838

PubMed: 29434772 ( click the link to review the publication )

Oncotarget, 2018, 9(45):27736-27751

PubMed: 29963233 ( click the link to review the publication )

Oncotarget, 2018, 9(21):15658-15672

PubMed: 29644000 ( click the link to review the publication )

Gut, 2017, 66(8):1358-1368

PubMed: 27196599 ( click the link to review the publication )

Clin Cancer Res, 2017, 23(22):6958-6968

PubMed: 28814434 ( click the link to review the publication )

Dev Cell, 2017, 43(4):449-462

PubMed: 29103955 ( click the link to review the publication )

Cell Syst, 2017, 5(3):237-250.e8

PubMed: 28843484 ( click the link to review the publication )
Oncogene, 2017, 36(16):2255-2264

PubMed: 27748766 ( click the link to review the publication )

Cancer Cell Int, 2017, 10.1186/s12935-017-0405-y

PubMed: 28286417 ( click the link to review the publication )

SLAS Discov, 2017, 22(5):507-515

PubMed: 28324660 ( click the link to review the publication )

Clin Cancer Res, 2017, 23(22):6946-6957

PubMed: 28830923 ( click the link to review the publication )

JCO Precis Oncol, 2017, 1PO.17.00140

PubMed: 32913968 ( click the link to review the publication )

Oncotarget, 2017, 8(33):55319-55331

PubMed: 28903422 ( click the link to review the publication )

Mol Cell, 2016, 64(5):875-887

PubMed: 27889448 ( click the link to review the publication )

Nat Commun, 2016, 7:11987

PubMed: 27329820 ( click the link to review the publication )

Cancer Res, 2016, 76(22):6723-6734

PubMed: 27634768 ( click the link to review the publication )

Mol Pharm, 2016, 13(11):3724-3735

PubMed: 27653969 ( click the link to review the publication )

Transl Oncol, 2016, 9(3):197-202

PubMed: 27267837 ( click the link to review the publication )

产品安全说明书

CDK抑制剂选择性比较

生物活性

产品描述

Ribociclib (LEE011) 是一种具有口服活性的、高度特异性的CDK4和CDK6抑制剂，对应的IC50值分别为10 nM和39 nM。Phase 3。

特性

口服生物有效的CDK4/6选择性抑制剂，处于Ⅲ期临床测试，用于晚期乳腺癌的治疗。

靶点

CDK4 ^[2] (Cell-free assay)	CDK6 ^[2] (Cell-free assay)
10 nM	39 nM

体外研究

LEE011是一种CDK4/CDK6的双重抑制剂，能够显著抑制17种神经细胞瘤中的12种的生长，平均IC50值是307 nM。对神经细胞瘤的抑制主要是抑制细胞的生长，受到G1细胞周期阻滞和细胞衰老的调控。

Cell Data

Cell Lines	Assay Type	Concentration	Incubation Time	Formulation	Activity Description	PMID
DFSP105	MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		M3P2[VI1KGh?		M4X3XWdKPTB;Mke2JI5O	MVi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTh3MkC1PEc,OjV6NUKwOVg9N2F-
Myoblast	MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		MojhO\|IhcA>?		NUPXWnJjUUN3ME2xNFM2KG6P	Mlq4QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV6MUCzO\|UoRjJ3OEGwN\|c2RC:jPh?=
IMRS	M{XXfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		NIHWVpE4OiCq		NHXYfJRKSzVyPUi3N{BvVQ>?	NWPBTGV7RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW4NVA{PzVpPkK1PFExOzd3PD;hQi=>
SKNAS	MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		NF;0dWw4OiCq		MXjJR\|Ux97zgMUCwNFAhdk1?	Ml2zQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV6MUCzO\|UoRjJ3OEGwN\|c2RC:jPh?=
Rh28	NIfJXJdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		MXe3NkBp		NYLCXW5nUUN3ME24OFUhdk1?	NWLCdnduRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW4NVA{PzVpPkK1PFExOzd3PD;hQi=>
Rh41	NF3KOopIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		NIXrN5A4OiCq		M3nP[mlEPTB;N{G4O{BvVQ>?	MVy8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPThzMEO3OUc,OjV6MUCzO\|U9N2F-
CW9019	MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		MXS3NkBp		NGnOOXFKSzVyPUm5NVIhdk1?	NYH3OlRqRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW4NVA{PzVpPkK1PFExOzd3PD;hQi=>
Rh5	MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		MnHhO\|IhcA>?		M{GwUWlEPTExvK6xNFAxOCCwTR?=	MU[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPThzMEO3OUc,OjV6MUCzO\|U9N2F-
Rh30	M3XHOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		M1L5WlczKGh?		NV;IdFA1UUN3MP-8olExODByIH7N	NG[zRVY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUixNFM4PSd-MkW4NVA{PzV:L3G+
778	M{fLVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		MlPUO\|IhcA>?		M4r1[4lvcGmkaYTzJINmdGxiZ4Lve5RpKGSxc3Wg[IVx\W6mZX70cJk>	Mn30QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjVyMki0OlkoRjJ3MEK4OFY6RC:jPh?=
449	MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		NXvrSW5OPzJiaB?=		NUPpOWVIcW6qaXLpeJMh[2WubDDndo94fGhiZH;z[UBl\XCnbnTlcpRtgQ>?	M3i4TVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3MEK4OFY6Lz5{NUCyPFQ3QTxxYU6=
LP3	NVy3fm1tT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		NH7CR4s4OiCq		NGXEcZhqdmirYnn0d{Bk\WyuIHfyc5d1cCCmb4PlJIRmeGWwZHXueIx6	NEPQ[2s9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUCyPFQ3QSd-MkWwNlg1Pjl:L3G+
LP6	MlPXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		M3ixdFczKGh?		NFGxVIVqdmirYnn0d{Bk\WyuIHfyc5d1cCCmb4PlJIRmeGWwZHXueIx6	MkDZQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjVyMki0OlkoRjJ3MEK4OFY6RC:jPh?=
LP8	NFnsUIxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		MkTZO\|IhcA>?		MVTpcohq[mm2czDj[YxtKGe{b4f0bEBld3OnIHTldIVv\GWwdHz5	MUm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTB{OES2PUc,OjVyMki0Olk9N2F-
LPS141	MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		NV;BbIhzPzJiaB?=		MW\pcohq[mm2czDj[YxtKGe{b4f0bEBld3OnIHTldIVv\GWwdHz5	NY\Ofod4RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkWwNlg1PjlpPkK1NFI5PDZ7PD;hQi=>
778	MmTIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NIroT3Y{NjN\|IN88US=>	M{W2XlI1KGh?		Ml\P[IVkemWjc3XzJJRp\SCycn;wc5J1cW:wIH;mJINmdGy\|IHnuJHMheGijc3W=	M3nSOVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3MEK4OFY6Lz5{NUCyPFQ3QTxxYU6=
449	MnnPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MlrUN{4{OyEQvF2=	Mk\DNlQhcA>?		NEOzTmZl\WO{ZXHz[ZMhfGinIIDyc5BwenSrb36gc4Yh[2WubIOgbY4hWyCyaHHz[S=>	NFnBeZA9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUCyPFQ3QSd-MkWwNlg1Pjl:L3G+
LP3	NFjWVlNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MmLMN{4{OyEQvF2=	NI\LboYzPCCq		NWG4Uml5\GWlcnXhd4V{KHSqZTDwdo9xd3K2aX;uJI9nKGOnbHzzJIlvKFNicHjhd4U>	M3X3UFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3MEK4OFY6Lz5{NUCyPFQ3QTxxYU6=
LP6	NXPOc3hJT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NELGN20{NjN\|IN88US=>	M4nDflI1KGh?		M{TBRoRm[3KnYYPld{B1cGVicILvdI9zfGmxbjDv[kBk\WyuczDpckBUKHCqYYPl	MUO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTB{OES2PUc,OjVyMki0Olk9N2F-
LP8	NWKyZWx1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MoizN{4{OyEQvF2=	M4L6PVI1KGh?		M1\sS4Rm[3KnYYPld{B1cGVicILvdI9zfGmxbjDv[kBk\WyuczDpckBUKHCqYYPl	MmLiQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjVyMki0OlkoRjJ3MEK4OFY6RC:jPh?=
LPS141	NX[5bFhWT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MUizMlM{KM7:TR?=	MkDHNlQhcA>?		MmL2[IVkemWjc3XzJJRp\SCycn;wc5J1cW:wIH;mJINmdGy\|IHnuJHMheGijc3W=	M3jZO\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3MEK4OFY6Lz5{NUCyPFQ3QTxxYU6=
IMR5	M2jIfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		NEjtXnAzPCCq	NVmzVFF7TE2VTx?=	MlfZTWM2OD1zMk[gcm0>	NWnnbIxqRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkSwOFUyPzlpPkK0NFQ2OTd7PD;hQi=>
BE2C	NGrC[mdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		M4jIZ\|I1KGh?	NXzVUXl1TE2VTx?=	MV7JR\|UxRTF\|NDDuUS=>	MYq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDB2NUG3PUc,OjRyNEWxO\|k9N2F-
1643	NXvjRmN6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		M2fYeFI1KGh?	NXeybnBRTE2VTx?=	NVfxe4J{UUN3ME2xOFchdk1?	M334bFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2MES1NVc6Lz5{NEC0OVE4QTxxYU6=
SKNSH	M1HlfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		M2L3dlI1KGh?	NGfPbGlFVVOR	MoKxTWM2OD1zNEigcm0>	NX[2cIVpRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkSwOFUyPzlpPkK0NFQ2OTd7PD;hQi=>
SY5Y	NH3y[mhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		MXWyOEBp	MXvEUXNQ	M{X3WWlEPTB;MUW0JI5O	M1n2bVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2MES1NVc6Lz5{NEC0OVE4QTxxYU6=
NGP	MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		Mn;xNlQhcA>?	MW\EUXNQ	MnyzTWM2OD1zN{Wgcm0>	MUi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDB2NUG3PUc,OjRyNEWxO\|k9N2F-
KELLY	NUXiVYN1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		NFy4NWkzPCCq	M1;YemROW09?	M3WwZ2lEPTB;MkKwJI5O	NXH2VpJDRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkSwOFUyPzlpPkK0NFQ2OTd7PD;hQi=>
CHP134	NGezTnZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		Mlj5NlQhcA>?	MWrEUXNQ	NFKwbnlKSzVyPUK3N{BvVQ>?	Mn3FQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjRyNEWxO\|koRjJ2MES1NVc6RC:jPh?=
NLF	M{nyfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		M{X2RVI1KGh?	NYWzU3dKTE2VTx?=	NITHN5FKSzVyPUOyPEBvVQ>?	MoDNQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjRyNEWxO\|koRjJ2MES1NVc6RC:jPh?=
LAN5	NUXiVXdnT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		NEDreGEzPCCq	Mlm4SG1UVw>?	NYrFdmg4UUN3ME20Nlkhdk1?	MY[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDB2NUG3PUc,OjRyNEWxO\|k9N2F-
NB69	NHPV[nZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		NI\2[GszPCCq	NYj2XYwzTE2VTx?=	MUTJR\|UxRTd\|ODDuUS=>	MoPxQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjRyNEWxO\|koRjJ2MES1NVc6RC:jPh?=
SKNDZ	M4qxXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		MlXHNlQhcA>?	MoLUSG1UVw>?	M4fSbWlEPTB;OECxJI5O	M32zTFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2MES1NVc6Lz5{NEC0OVE4QTxxYU6=
NBSD	NX7ONGlZT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		NETlOG4zPCCq	M4XXZmROW09?	MnzMTWM2OD1zOUCwJI5O	MmTDQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjRyNEWxO\|koRjJ2MES1NVc6RC:jPh?=
SKNF1	NVqyUGh[T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		NY\2ZVRmOjRiaB?=	MnLhSG1UVw>?	M4jTW2lEPTB;M{WwNEBvVQ>?	M1;zS\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2MES1NVc6Lz5{NEC0OVE4QTxxYU6=
EBC1	M4G0Omdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		NYPyfohHOjRiaB?=	MVnEUXNQ	NF3COXVKSzVyPU[0NFAhdk1?	MUi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDB2NUG3PUc,OjRyNEWxO\|k9N2F-
SKNAS	NYHSZ2dbT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		NHrUeG0zPCCq	NYqxV5FnTE2VTx?=	NVzD[GVVUUN3MP-8olExODByIH7N	NF63coY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEC0OVE4QSd-MkSwOFUyPzl:L3G+
NB16	NX\ZUHN5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		MX:yOEBp	M3LJWGROW09?	MY\JR\|Ux97zgMUCwNFAhdk1?	M2LVZlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2MES1NVc6Lz5{NEC0OVE4QTxxYU6=
RPE1	MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		NF[1blYzPCCq	NVfTWWdNTE2VTx?=	NFnZTGpKSzVy78{eNVAxODBibl2=	NX7YdVFMRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkSwOFUyPzlpPkK0NFQ2OTd7PD;hQi=>
Sf21	NYDLRZZiTnWwY4Tpc44h[XO\|YYm=		MnfUNVAhdWmwcx?=		MnrnTY5pcWKrdHnvckBw\iC{ZXPvcYJqdmGwdDDoeY1idiCodXzsJIxmdme2aDDOMZRmem2rbnHsJGdUXC22YXfn[YQhS0SNND;DfYNtcW5vREOgZ48u\XiycnXzd4VlKGmwIHLhZ5Vtd3[rcoXzJIlv\mWldHXkJJNnOjFiY3XscJMhfXOrbnegVoIhe3Wkc4TyZZRmKGmwIIDy[ZNmdmOnIH;mJHto[W2vYUOzVH1CXFBiYX\0[ZIhOTBibXnud{BjgSC\|Y3nueIltdGG2aX;uJINwfW62aX7nJI1mfGixZDygTWM2OCB;IECuNFE{KM7:TT6=	NYLsXY1rRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm1NVg{OTJpPkK5OVE5OzF{PD;hQi=>
Sf21	MmOxSpVv[3Srb36gZZN{[Xl?		NGDvfY0yOCCvaX7z		NXr4b4tHUW6qaXLpeIlwdiCxZjDy[YNwdWKrbnHueEBpfW2jbjDmeYxtKGynbnf0bEBENXSncn3pcoFtKD[KaYOteIFo\2WmIFPET\|kwS3mlbHnuMXQyKGOxLXX4dJJme3OnZDDpckBj[WO3bH;2bZJ2eyCrbn\lZ5Rm\CC\|ZkKxJINmdGy\|IIXzbY5oKFCGS4Tp[IUhe3Wkc4TyZZRmKGmwIIDy[ZNmdmOnIH;mJHto[W2vYUOzVH1CXFBiYX\0[ZIhOTBibXnud{BjgSC\|Y3nueIltdGG2aX;uJINwfW62aX7nJI1mfGixZDygTWM2OCB;IECuNVk4KM7:TT6=	MVq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTVzOEOxNkc,Ojl3MUizNVI9N2F-
HepG2	NFLFNWdCdnSrcILvcIln\XKjdHn2[UBie3OjeR?=		NVy3NFBGPzJiaILz		MWHBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKEincFeyJINmdGy\|IHHmeIVzKDd{IHjyd{BjgSCFZXzUbZRmei2JbH:gZZN{[XluIFXDOVAhRSByLkK4OlIh\|ryPLh?=	NWDITWFWRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0NFc6PzVpPkK5OFA4QTd3PD;hQi=>
SEM	M3PUT2FvfGmycn;sbYZmemG2aY\lJIF{e2G7		MoLoO\|IhcHK\|		NX:yUFZbSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDTSW0h[2WubIOgZYZ1\XJiN{KgbJJ{KGK7IFPlcHRqfGW{LVfsc{Bie3OjeTygSWM2OCB;IECuOFYxPSEQvF2u	M4jp[VxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEC3PVc2Lz5{OUSwO\|k4PTxxYU6=
KOPN8	MVzBcpRqeHKxbHnm[ZJifGm4ZTDhd5NigQ>?		MnLFO\|IhcHK\|		NVv6dFB1SW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDLU3BPQCClZXzsd{Bi\nSncjC3NkBpenNiYomgR4VtXGm2ZYKtS4xwKGG\|c3H5MEBGSzVyIE2gNE42ODB6IN88UU4>	MlXUQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2MEe5O\|UoRjJ7NEC3PVc2RC:jPh?=
NCI-H1299	NH\leWFEgXSxdH;4bYNqfHliYYPzZZk>		MWi3NkBpenN?		M{PLe2N6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJG5EUS2KMUK5PUBk\WyuczDhd5Nme3OnZDDhd{Bz\WS3Y4Tpc44hcW5iY3XscEB3cWGkaXzpeJkh[W[2ZYKgO\|IhcHK\|IHL5JGNEUzhiYYPzZZktKEmFNUCgQUA2NjR4IN88UU4>	NGrlcFI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUWxPFMyOid-Mkm1NVg{OTJ:L3G+
T47D	MmT3S5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?		NIraUng4OiCqcoO=		NITQSWNIem:5dHigbY5pcWKrdHnvckBw\iCqdX3hckBVPDeGIHPlcIx{KGmwY4XiZZRm\CCob4KgO\|IhcHK\|IHL5JGNEUzhiYYPzZZktKEmFNUCgQUA3NjJ{NzFOwG0v	M4P5NFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ6NkWxPVc6Lz5{OE[1NVk4QTxxYU6=
T47D	M1TTV2N6fG:2b4jpZ4l1gSCjc4PhfS=>		MnX2O\|IhcHK\|		MorBR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gWFQ4TCClZXzsd{Bie3Onc4Pl[EBieyC{ZXT1Z5Rqd25iaX6gZ4VtdCC4aXHibYxqfHliYX\0[ZIhPzJiaILzJIJ6KEOFS{igZZN{[XluIFnDOVAhRSB4LkKzJO69VS5?	NGnMcYM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUWxPFMyOid-Mkm1NVg{OTJ:L3G+
H1299	M33Pemdzd3e2aDDpcohq[mm2aX;uJIF{e2G7		M4nqXlczKGi{cx?=		MX7Hdo94fGhiaX7obYJqfGmxbjDv[kBpfW2jbjDINVI6QSClZXzsd{BqdmO3YnH0[YQh\m:{IEeyJIhzeyCkeTDDR2s5KGG\|c3H5MEBKSzVyIE2gO{43OzdizszNMi=>	MY[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQDZ3MUm3PUc,Ojh4NUG5O\|k9N2F-
KOPN8	M2f3UmFxd3C2b4Ppd{Bie3OjeR?=	NH3lUYwxNjVidV2=	MkS4N{BpenN?		M3;rO2lv\HWldHnvckBw\iCjcH;weI9{cXNiaX6gbJVu[W5iS1;QUlgh[2WubIOgZZN{\XO\|ZXSgZZMhfXC{ZXf1cIF1cW:wIH;mJINt\WG4ZXSgVGFTWCCuZY\lcEBifCByLkWgeW0h[W[2ZYKgN{BpenNiYomgW4V{fGW{bjDicI91KGGwYXz5d4l{	NHmxVYs9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSwO\|k4PSd-Mkm0NFc6PzV:L3G+
KOPN8	NI\nXHRCeG:ydH;zbZMh[XO\|YYm=	NXj4boNSOC53IIXN	NEe5RpYzPCCqcoO=		NH;EV5dKdmS3Y4Tpc44hd2ZiYYDvdJRwe2m\|IHnuJIh2dWGwIFvPVG45KGOnbHzzJIF{e2W\|c3XkJIF{KHWycnXneYxifGmxbjDv[kBkdGWjdnXkJHBCWlBibHX2[Ywh[XRiMD61JJVOKHC{ZT30doVifGWmIIfpeIghVkGFIH\vdkAyKGi{IHHu[EBu\WG\|dYLl[EBi\nSncjCyOEBpenNiYomgW4V{fGW{bjDicI91KGGwYXz5d4l{	MVW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTRyN{m3OUc,Ojl2MEe5O\|U9N2F-
Hep3B	NIf6WFVE\WyuIHP5Z4xmKGG\|c3H5		MVmyOEBpenN?		NIeyO2tE\WyuIHP5Z4xmKGG{cnXzeEBqdiCqdX3hckBJ\XB\|QjDj[YxteyCjc4Pld5Nm\CCjczDhZ4N2dXWuYYTpc44h[XRiR{CvS\|EheGijc3WgZYZ1\XJiMkSgbJJ{KGK7IIDyc5Bq\Gm3bTDpc4Rq\GVic4ThbY5qdmdiYnHz[YQh\myxdzDjfZRwdWW2com=	M3j5XlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NUG4N\|EzLz5{OUWxPFMyOjxxYU6=
HepG2	MkjOR4VtdCCleXPs[UBie3OjeR?=		M4HZVFI1KGi{cx?=		NVLGWoRWS2WubDDjfYNt\SCjcoLld5QhcW5iaIXtZY4hUGWyR{KgZ4VtdHNiYYPz[ZN{\WRiYYOgZYNkfW23bHH0bY9vKGG2IFewM2cyKHCqYYPlJIFnfGW{IEK0JIhzeyCkeTDwdo9xcWSrdX2gbY9lcWSnIIP0ZYlvcW6pIHLhd4VlKG[ub4egZ5l1d22ndIL5	MlTCQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl3MUizNVIoRjJ7NUG4N\|EzRC:jPh?=
A549	NWH0NYtUS2WubDDjfYNt\SCjc4PhfS=>		NGHoXoQzPCCqcoO=		NGi5[VBE\WyuIHP5Z4xmKGG{cnXzeEBqdiCqdX3hckBCPTR7IHPlcIx{KGG\|c3Xzd4VlKGG\|IHHjZ5VufWyjdHnvckBifCCJMD;HNUBxcGG\|ZTDh[pRmeiB{NDDodpMh[nlicILvdIllcXWvIHnv[Ill\SC\|dHHpcolv\yCkYYPl[EBndG:5IHP5eI9u\XS{eR?=	M{L0PVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NUG4N\|EzLz5{OUWxPFMyOjxxYU6=
NCI-H460	NV;M[nc3S2WubDDjfYNt\SCjc4PhfS=>		MXGyOEBpenN?		MWLD[YxtKGO7Y3zlJIFzemW\|dDDpckBpfW2jbjDOR2kuUDR4MDDj[YxteyCjc4Pld5Nm\CCjczDhZ4N2dXWuYYTpc44h[XRiR{CvS\|EheGijc3WgZYZ1\XJiMkSgbJJ{KGK7IIDyc5Bq\Gm3bTDpc4Rq\GVic4ThbY5qdmdiYnHz[YQh\myxdzDjfZRwdWW2com=	NG\BRlk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUWxPFMyOid-Mkm1NVg{OTJ:L3G+
T47D	M1PrfWNmdGxiY4njcIUh[XO\|YYm=		MnP2NlQhcHK\|		MW\D[YxtKGO7Y3zlJIFzemW\|dDDpckBpfW2jbjDUOFdFKGOnbHzzJIF{e2W\|c3XkJIF{KGGlY4XteYxifGmxbjDheEBIOC:JMTDwbIF{\SCjZoTldkAzPCCqcoOgZpkheHKxcHnkbZVuKGmxZHnk[UB{fGGrbnnu[{Bj[XOnZDDmcI94KGO7dH;t[ZRzgQ>?	MXq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTVzOEOxNkc,Ojl3MUizNVI9N2F-
MDA-MB-231	MX7D[YxtKGO7Y3zlJIF{e2G7		M1vlWVI1KGi{cx?=		M3X3cmNmdGxiY4njcIUh[XK{ZYP0JIlvKGi3bXHuJG1FSS2PQj2yN\|Eh[2WubIOgZZN{\XO\|ZXSgZZMh[WOldX31cIF1cW:wIHH0JGcxN0dzIIDoZZNmKGGodHXyJFI1KGi{czDifUBxem:yaXTpeY0hcW:maXTlJJN1[WmwaX7nJIJie2WmIH\sc5ch[3m2b33leJJ6	NIfBVnE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUWxPFMyOid-Mkm1NVg{OTJ:L3G+
Fluc-labeled 4T1	MojFRY51cXS3bX;yJIF{e2G7	MVmxN\|AhdWdxa3e=	MXKxPEBl[Xm\|		MVHBcpRqfHWvb4KgZYN1cX[rdImgZYdicW6\|dDDtc5V{\SCIbIXjMYxi[mWuZXSgOHQyKGOnbHzzJIlueGyjboTl[EBqdiCEYXziM4MhdW:3c3WgZZN{\XO\|ZXSgZZMhemWmdXP0bY9vKGmwIIT1cY9zKHenaXfoeEBifCBzM{CgcYcwc2duIHnwJIFldWmwaYP0[ZJm\CCmYXnsfUBnd3JiMUig[IF6eyCvZXHzeZJm\CCjZoTldkA5KHSxIEK1JIRigXN?	NFrjU2Y9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUWxPFMyOid-Mkm1NVg{OTJ:L3G+
T47D	M2PYZmNmdGxiY4njcIUh[XO\|YYm=		NEfJXI0zPCCqcoO=		MkfFTY5lfWO2aX;uJI9nKGOnbHygZ5lkdGViYYLy[ZN1KGmwIHj1cYFvKFR2N1SgZ4VtdHNiYYPz[ZN{\WRiYYOgbY5kemWjc3WgbY4hTzBxR{GgdIhie2ViYXPjeY12dGG2aX;uJIlv[3WkYYTl[EBnd3JiMkSgbJJ{KGK7IH\sc5ch[3m2b33leJJ6	M2PKb\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ6NkWxPVc6Lz5{OE[1NVk4QTxxYU6=

... Click to View More Cell Line Experimental Data

Assay

Methods	Test Index	PMID
Western blot	pRb(S807) / Rb / p53 / Cyclin E / Cyclin D1 / CDK4 / CDK6 / p27 / p21 / PARP; PubMed: 29789630 Sci Rep Effect of ribociclib on pRB and G1 cell cycle regulating protein expressions in C666-1 and HK1 cells. Cells were treated with ribociclib in 2 concentrations, one of them near their corresponding IC50, for 24 and 48 hours. Phosphorylation of Rb in all cell䲧疝Ỵ疞㧀疜膉痘 瘿뾠ՂᾰƌՂĀ 㺣痖帉痖Ѐ瑖堘𢡄빢᎒ՂĀ鑸᎒彿堙奋堙巫堙᎒ﻺ᎒彿堙ﻮ᎒塚堙ﻺ᎒ꍈ堞빢᎒學堙漸堞圔堙빢᎒圞堙圭堙𢡄玚Wᾰƌ ᾰƌ戤瘯Ɖ⟸෕䐺痖暼瘿⟸෕ᾰƌ ⟸෕Ð㺣痖⟸෕𢡄⟼෕䀷痗⟼෕౴⟼෕	29789630
Growth inhibition assay	Cell viability ; PubMed: 26390342 ACS Chem Biol Effects of palbociclib and ribociclib on viability of H157, H2170, H520 and H596 cells after 72 hours of drug treatment and IC50 values for inhibition of cell viability.	26390342

体内研究

LEE011 (200 mg/kg 每日，口服)引起小鼠中的BE2C 或者 1643细胞显著的生长延迟，没有体重减轻或者其它的毒性症状。^[1]

细胞实验： [1]	- 合并 Cell lines: BE2C, IMR5, 1643, SY5Y, CHP134, SKNSH, NGP, KELLY, LAN5, NLF, NB69, SKNDZ, NBSD, NBLS, SKNFI, EBC1, SKNAS, NB16, RPE1细胞系。 Concentrations: 10 μM Incubation Time: ~100小时 Method: 将板中优先附着基底生长的神经母细胞瘤细胞系以一式三份种植于Xcelligence实时细胞电子传感系统，用4个剂量梯度的抑制剂和DMSO为对照处理细胞24小时。连续监测细胞约100个小时，IC50通过以下方法测得：通过绘制细胞指数为时间的函数产生生长曲线，以在治疗开始时细胞指数为1作为标准。从治疗开始到处理96小时后，生长曲线下的面积通过基线下面积为1（治疗开始时的细胞指数）进行计算。积分面积以DMSO处理的对照组作为背景。抑制剂比上对照组的值取非线性对数值来计算。所有的实验至少重复一次。 (Only for Reference)
动物实验： ^[1]	- 合并 Animal Models: BE2C, NB-1643,或EBC1异种移植的小鼠。 Dosages: ~200毫克/千克每天 Administration: 口服 (Only for Reference)

参考文献

溶解度 (25°C)

体外	DMSO	7 mg/mL (16.1 mM)
	Water	Insoluble
	Ethanol	Insoluble

* 溶解度检测是由Selleck技术部门检测的，可能会和文献中提供的溶解度有所差异，这是由于生产工艺和批次不同产生的正常现象。请按照顺序依次加入各个纯溶剂。

化学数据 Download Ribociclib (LEE011) SDF

分子量	434.54
化学式	C₂₃H₃₀N₈O
CAS号	1211441-98-3
储存条件	3年-20°C 粉状 2年-80°C 溶于溶剂
别名	N/A

动物体内配方计算器 (澄清溶液)

第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量）

给药剂量

mg/kg

动物平均体重

每只动物给药体积

动物数量

只

第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系Selleck为您提供正确的澄清溶液配方）

% DMSO+ % + % Tween 80+ % ddH₂O

计算重置

计算结果:

工作液浓度： mg/ml；

DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，注：如该浓度超过该批次药物DMSO溶解度，请先联系Selleck）；

体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL ddH₂O，混匀澄清。

注意：1. 首先保证母液是澄清的；
2. 一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。

计算器

摩尔浓度计算器

本计算器可帮助您计算出特定溶液中溶质的质量、溶液浓度和体积之间的关系，公式为:

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子量 (g/mol)

摩尔浓度计算公式

质量

浓度

体积

分子量
=

×

×

*在配置溶液时，请务必参考Selleck产品标签上、SDS / COA（可在Selleck的产品页面获得）批次特异的分子量使用本工具。

稀释计算器

用本工具协助配置特定浓度的溶液，使用的计算公式为：

开始浓度 x 开始体积 = 最终浓度 x 最终体积

稀释公式

稀释公式一般简略地表示为: C1V1 = C2V2 ( 输入输出 )

C1

V1

C2

V2
×

=

×

在配置溶液时，请务必参考Selleck产品标签上、SDS / COA（可在Selleck的产品页面获得）批次特异的分子量使用本工具。.

连续稀释计算器方程

连续稀释
初始浓度:
稀释倍数:

计算结果

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

分子量计算器

通过输入化合物的化学式来计算其分子量：

注：化学分子式大小写敏感。C10H16N2O2 c10h16n2o2

摩尔浓度计算器

质量	浓度	体积	分子量
=	×	×
计算

临床试验信息 (data from https://clinicaltrials.gov, updated on 2021-09-06)

NCT Number	Recruitment	interventions	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT04657679	Recruiting	Drug: Ribociclib	Breast Cancer	Georgetown University\|Medstar Health Research Institute\|Breast Cancer Research Foundation\|Georgetown-Howard Universities Center for Clinical and Translational Science (GHUCCTS)	May 20 2021	--
NCT04315233	Recruiting	Drug: Ribociclib\|Drug: Belinostat	Metastatic Breast Cancer\|Recurrent Ovarian Carcinoma	University of Utah\|Novartis\|Acrotech Biopharma	October 29 2020	Phase 1
NCT04417621	Recruiting	Drug: LXH254\|Drug: LTT462\|Drug: Trametinib\|Drug: Ribociclib	Melanoma	Novartis Pharmaceuticals\|Novartis	October 30 2020	Phase 2

技术支持

在订购、运输、储存和使用我们的产品的任何阶段，您遇到的任何问题，均可以通过拨打我们的热线电话400-668-6834，或者技术支持邮箱tech@selleck.cn，直接联系到我们。我们会在24小时内尽快联系您。

操作手册

如果有其他问题，请给我们留言。

研究领域

产品类型

定制您的化合物库

Ribociclib (LEE011)

客户使用Selleck生产的Ribociclib (LEE011)发表文献59篇：

产品安全说明书

CDK抑制剂选择性比较

生物活性

推荐的实验操作(此推荐来自于公开的文献所以Selleck并不保证其有效性)

参考文献

溶解度 (25°C)

化学数据 Download Ribociclib (LEE011) SDF

动物体内配方计算器 (澄清溶液)

计算器

摩尔浓度计算器

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子量 (g/mol)

摩尔浓度计算公式

稀释计算器

开始浓度 x 开始体积 = 最终浓度 x 最终体积

稀释公式

连续稀释计算器方程

连续稀释

计算结果

分子量计算器

总分子量：g/mol

摩尔浓度计算器

临床试验信息 (data from https://clinicaltrials.gov, updated on 2021-09-06)

技术支持

CDK Signaling Pathway Map

相关CDK产品